631 related articles for article (PubMed ID: 25425963)
21. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
22. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
23. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
24. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
[TBL] [Abstract][Full Text] [Related]
25. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
[TBL] [Abstract][Full Text] [Related]
26. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
27. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
28. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Nakajima Y; Akaogi K; Suzuki T; Osakabe A; Yamaguchi C; Sunahara N; Ishida J; Kako K; Ogawa S; Fujimura T; Homma Y; Fukamizu A; Murayama A; Kimura K; Inoue S; Yanagisawa J
Sci Signal; 2011 Apr; 4(168):ra22. PubMed ID: 21487105
[TBL] [Abstract][Full Text] [Related]
29. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
30. Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.
Pascal LE; Su F; Wang D; Ai J; Song Q; Wang Y; O'Malley KJ; Cross B; Rigatti LH; Green A; Dhir R; Wang Z
Neoplasia; 2019 Aug; 21(8):752-764. PubMed ID: 31229879
[TBL] [Abstract][Full Text] [Related]
31. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
32. DGCR8 is essential for tumor progression following PTEN loss in the prostate.
Belair CD; Paikari A; Moltzahn F; Shenoy A; Yau C; Dall'Era M; Simko J; Benz C; Blelloch R
EMBO Rep; 2015 Sep; 16(9):1219-32. PubMed ID: 26206718
[TBL] [Abstract][Full Text] [Related]
33. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
[TBL] [Abstract][Full Text] [Related]
34. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
[TBL] [Abstract][Full Text] [Related]
35. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.
Adisetiyo H; Liang M; Liao CP; Aycock-Williams A; Cohen MB; Xu S; Neamati N; Conway EM; Cheng CY; Nikitin AY; Roy-Burman P
PLoS One; 2013; 8(7):e69484. PubMed ID: 23936028
[TBL] [Abstract][Full Text] [Related]
36. Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice.
Blando JM; Carbajal S; Abel E; Beltran L; Conti C; Fischer S; DiGiovanni J
Neoplasia; 2011 Mar; 13(3):254-65. PubMed ID: 21390188
[TBL] [Abstract][Full Text] [Related]
37. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
38. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
40. TGFβ signaling limits lineage plasticity in prostate cancer.
Hao Y; Bjerke GA; Pietrzak K; Melhuish TA; Han Y; Turner SD; Frierson HF; Wotton D
PLoS Genet; 2018 May; 14(5):e1007409. PubMed ID: 29782499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
